                         SEQUENCE LISTING

<110>  Agency for Science, Technology and Research
 
<120>  Anti-PD-1 Antibodies

<130>  RIC/FP7150477

<150>  GB 1419084.7
<151>  2014-10-27

<160>  89    

<170>  PatentIn version 3.3

<210>  1
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Light chain variable domain sequence for 
       anti-PD-1 antibody clone A3

<400>  1

Leu Pro Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Lys Phe Asn 
            20                  25                  30          


Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Phe Cys Ala Ser Trp Asp Asp Val Leu 
                85                  90                  95      


Tyr Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  2
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Light chain variable domain sequence for 
       anti-PD-1 antibody clone A10

<400>  2

Leu Pro Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Lys Phe Asn 
            20                  25                  30          


Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Phe Cys Ala Ser Trp Asp Asp Tyr Tyr 
                85                  90                  95      


Tyr Gly Thr Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  3
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Light chain variable domain sequence for 
       anti-PD-1 antibody clone B6

<400>  3

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Lys Phe Asn 
            20                  25                  30          


Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Asp Tyr Leu 
                85                  90                  95      


Arg Gly Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  4
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Light chain variable domain sequence for 
       anti-PD-1 antibody clone C4

<400>  4

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Lys Phe Asn 
            20                  25                  30          


Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ala Trp Asp Asp Tyr Leu 
                85                  90                  95      


His Gly Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  5
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Light chain variable domain sequence for 
       anti-PD-1 antibody clone D4

<400>  5

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Lys Phe Asn 
            20                  25                  30          


Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Asp Tyr Val 
                85                  90                  95      


Arg Gly Thr Met Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  6
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Light chain variable domain sequence for 
       anti-PD-1 antibody clone E1

<400>  6

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Lys Phe Asn 
            20                  25                  30          


Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Trp Asp Asp Phe Leu 
                85                  90                  95      


Arg Gly Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  7
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Light chain variable domain sequence for 
       anti-PD-1 antibody clone F2

<400>  7

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Lys Phe Asn 
            20                  25                  30          


Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Trp Asp Asp Asp Ala 
                85                  90                  95      


Arg Gly Thr Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  8
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Light chain variable domain sequence for 
       anti-PD-1 antibody clone G1

<400>  8

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Lys Phe Asn 
            20                  25                  30          


Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Val Tyr 
                85                  90                  95      


Tyr Gly Thr Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  9
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Light chain variable domain sequence for 
       anti-PD-1 antibody clone G2

<400>  9

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Lys Phe Asn 
            20                  25                  30          


Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Asp Ser Leu 
                85                  90                  95      


Tyr Gly Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  10
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Light chain variable domain sequence for 
       anti-PD-1 antibody clone G10

<400>  10

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Lys Phe Asn 
            20                  25                  30          


Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ala Tyr 
                85                  90                  95      


Tyr Gly Thr Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  11
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Light chain variable domain sequence for 
       anti-PD-1 antibody clone H4

<400>  11

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Lys Phe Asn 
            20                  25                  30          


Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Asp Val Tyr 
                85                  90                  95      


Arg Gly Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  12
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Light chain variable domain sequence for 
       anti-PD-1 antibody clone H9

<400>  12

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Lys Phe Asn 
            20                  25                  30          


Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Trp Asp Asp Ser Leu 
                85                  90                  95      


Tyr Gly Thr Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  13
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Heavy chain variable domain sequence for 
       anti-PD-1 antibody clone A3

<400>  13

Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Lys Asp His Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  14
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Heavy chain variable domain sequence for 
       anti-PD-1 antibody clone A10

<400>  14

Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Lys Asp Val Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  15
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Heavy chain variable domain sequence for 
       anti-PD-1 antibody clone B6

<400>  15

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Asp Tyr Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  16
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Heavy chain variable domain sequence for 
       anti-PD-1 antibody clone C4

<400>  16

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Leu Asp Val Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  17
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Heavy chain variable domain sequence for 
       anti-PD-1 antibody clone D4

<400>  17

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  18
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Heavy chain variable domain sequence for 
       anti-PD-1 antibody clone E1

<400>  18

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  19
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Heavy chain variable domain sequence for 
       anti-PD-1 antibody clone F2

<400>  19

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  20
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Heavy chain variable domain sequence for 
       anti-PD-1 antibody clone G1

<400>  20

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  21
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Heavy chain variable domain sequence for 
       anti-PD-1 antibody clone G2

<400>  21

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  22
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Heavy chain variable domain sequence for 
       anti-PD-1 antibody clone G10

<400>  22

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Asp Tyr Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  23
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Heavy chain variable domain sequence for 
       anti-PD-1 antibody clone H4

<400>  23

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Asp Leu Gly Ser Gly Tyr Tyr Leu Tyr Gly Met Asp Val Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  24
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Heavy chain variable domain sequence for 
       anti-PD-1 antibody clone H9

<400>  24

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  25
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR1

<400>  25

Ser Gly Ser Ser Ser Asn Ile Lys Phe Asn Ser Val Asn 
1               5                   10              


<210>  26
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR2

<400>  26

Ser Asn Asn Gln Arg Pro Ser 
1               5           


<210>  27
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR3

<400>  27

Ala Ser Trp Asp Asp Val Leu Tyr Gly Ser Val 
1               5                   10      


<210>  28
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR3

<400>  28

Ala Ser Trp Asp Asp Tyr Tyr Tyr Gly Thr Ile 
1               5                   10      


<210>  29
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR3

<400>  29

Ala Ser Trp Asp Asp Tyr Leu Arg Gly Thr Val 
1               5                   10      


<210>  30
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR3

<400>  30

Ser Ala Trp Asp Asp Tyr Leu His Gly Thr Val 
1               5                   10      


<210>  31
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR3

<400>  31

Ala Ser Trp Asp Asp Tyr Val Arg Gly Thr Met 
1               5                   10      


<210>  32
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR3

<400>  32

Ser Ser Trp Asp Asp Phe Leu Arg Gly Thr Val 
1               5                   10      


<210>  33
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR3

<400>  33

Ser Ser Trp Asp Asp Asp Ala Arg Gly Thr Ile 
1               5                   10      


<210>  34
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR3

<400>  34

Ala Ala Trp Asp Asp Val Tyr Tyr Gly Thr Ile 
1               5                   10      


<210>  35
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR3

<400>  35

Ala Ser Trp Asp Asp Ser Leu Tyr Gly Thr Val 
1               5                   10      


<210>  36
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR3

<400>  36

Ala Ala Trp Asp Asp Ala Tyr Tyr Gly Thr Ile 
1               5                   10      


<210>  37
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR3

<400>  37

Ala Ser Trp Asp Asp Val Tyr Arg Gly Thr Val 
1               5                   10      


<210>  38
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR3

<400>  38

Ser Ser Trp Asp Asp Ser Leu Tyr Gly Thr Ile 
1               5                   10      


<210>  39
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR1

<400>  39

Gly Phe Thr Phe Ser Ser Tyr Gly Met His 
1               5                   10  


<210>  40
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR2

<400>  40

Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  41
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR3

<400>  41

Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Lys Asp His 
1               5                   10              


<210>  42
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR3

<400>  42

Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Lys Asp Val 
1               5                   10              


<210>  43
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR3

<400>  43

Asp Tyr Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val 
1               5                   10              


<210>  44
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR3

<400>  44

Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Leu Asp Val 
1               5                   10              


<210>  45
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR3

<400>  45

Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val 
1               5                   10              


<210>  46
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR3

<400>  46

Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val 
1               5                   10              


<210>  47
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR3

<400>  47

Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val 
1               5                   10              


<210>  48
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR3

<400>  48

Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val 
1               5                   10              


<210>  49
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR3

<400>  49

Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val 
1               5                   10              


<210>  50
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR3

<400>  50

Asp Tyr Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val 
1               5                   10              


<210>  51
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR3

<400>  51

Asp Leu Gly Ser Gly Tyr Tyr Leu Tyr Gly Met Asp Val 
1               5                   10              


<210>  52
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR3

<400>  52

Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Met Asp Val 
1               5                   10              


<210>  53
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: LC-CDR3


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa= Ala or Ser

<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa= Ser or Ala

<220>
<221>  VARIANT
<222>  (6)..(6)
<223>  Xaa= Val, Tyr, Phe, Asp, Ser or Ala

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa= Leu, Tyr, Val or Ala

<220>
<221>  VARIANT
<222>  (8)..(8)
<223>  Xaa= Tyr, Arg or His

<220>
<221>  VARIANT
<222>  (10)..(10)
<223>  Xaa= Ser, or Thr

<220>
<221>  VARIANT
<222>  (11)..(11)
<223>  Xaa= Val, Ile, or Met

<400>  53

Xaa Xaa Trp Asp Asp Xaa Xaa Xaa Gly Xaa Xaa 
1               5                   10      


<210>  54
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR3


<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa= Leu or Tyr

<220>
<221>  VARIANT
<222>  (4)..(4)
<223>  Xaa= Ala or Ser

<220>
<221>  VARIANT
<222>  (6)..(6)
<223>  Xaa= Pro or Tyr

<220>
<221>  VARIANT
<222>  (8)..(8)
<223>  Xaa= Tyr or Leu

<220>
<221>  VARIANT
<222>  (11)..(11)
<223>  Xaa= Lys, Met or Leu

<220>
<221>  VARIANT
<222>  (13)..(13)
<223>  Xaa= His or Val

<400>  54

Asp Xaa Gly Xaa Gly Xaa Tyr Xaa Tyr Gly Xaa Asp Xaa 
1               5                   10              


<210>  55
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody clone A3

<400>  55
ctgcctgtgc tgactcagcc cccctcagcg tccgggaccc ccgggcagag ggtcaccatc     60

tcttgttctg gaagcagctc caacatcaaa tttaacagtg ttaactggta tcagcaactc    120

ccaggaacgg cccccaaact cctcatctat agtaataatc agcgaccctc aggggtccct    180

gaccgattct ctggctccaa gtctggcact tcagcctccc tggccatcag tgggctccag    240

tctgaggatg aggctgatta tttctgtgct tcttgggatg atgttcttta tggatctgtg    300

ttcggcggag ggaccaagct gaccgtcctg                                     330


<210>  56
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody clone A10

<400>  56
ctgcctgtgc tgactcagcc cccctcagcg tccgggaccc ccgggcagag ggtcaccatc     60

tcttgttctg gaagcagctc caacatcaaa tttaacagtg ttaactggta tcagcaactc    120

ccaggaacgg cccccaaact cctcatctat agtaataatc agcgaccctc aggggtccct    180

gaccgattct ctggctccaa gtctggcact tcagcctccc tggccatcag tgggctccag    240

tctgaggatg aggctgatta tttctgtgct tcttgggatg attattatta tggaactatt    300

ttcggcggag ggaccaagct gaccgtcctg                                     330


<210>  57
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Encoded amino acid sequence of light chain 
       variable domain sequence for anti-PD-1 antibody codon-optimised 
       clone A10

<400>  57

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Lys Phe Asn 
            20                  25                  30          


Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Asp Tyr Tyr 
                85                  90                  95      


Tyr Gly Thr Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  58
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody codon-optimised clone A10

<400>  58
cagagcgtcc tgacacagcc tcctagtgca agcggaaccc ctgggcagag agtgaccatt     60

tcttgtagcg gcagcagcag taacatcaag ttcaactccg tgaattggta tcagcagctg    120

cccggaactg ctcctaaact gctgatctac tctaacaatc agcgaccaag tggcgtcccc    180

gaccggttca gcggctccaa gtctgggacc agtgcctcac tggctatcag cgggctccag    240

tccgaggacg aagcagatta ctattgcgcc agctgggacg attactatta cggcaccatt    300

ttcggcgggg gaacaaaact gaccgtcctg                                     330


<210>  59
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody clone B6

<400>  59
cagtctgtgc tgactcagcc cccctcagcg tccgggaccc ccgggcagag ggtcaccatc     60

tcttgttctg gaagcagctc caacatcaaa tttaacagtg ttaactggta tcagcaactc    120

ccaggaacgg cccccaaact cctcatctat agtaataatc agcgaccctc aggggtccct    180

gaccgattct ctggctccaa gtctggcact tcagcctccc tggccatcag tgggctccag    240

tctgaggatg aggctgatta ttactgtgct tcttgggatg attatcttcg tggaactgtt    300

ttcggcggag ggaccaagct gaccgtcctg                                     330


<210>  60
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody codon-optimised clone B6

<400>  60
cagagcgtgc tgacccagcc ccccagcgcc agtggaacac ccggacagag agtgaccatc     60

agttgctcag gcagctcctc taacattaag ttcaactctg tgaattggta tcagcagctg    120

cccggaactg ctcctaaact gctgatctat tctaacaatc agcgaccaag tggcgtcccc    180

gaccggttca gcggctccaa gtctgggacc agtgcctcac tggctattag cgggctccag    240

tccgaggacg aagcagatta ctattgtgcc agctgggacg attacctgag gggcaccgtg    300

ttcggaggag gaacaaaact gaccgtcctg                                     330


<210>  61
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody clone C4

<400>  61
cagtctgtgc tgactcagcc cccctcagcg tccgggaccc ccgggcagag ggtcaccatc     60

tcttgttctg gaagcagctc caacatcaaa tttaacagtg ttaactggta tcagcaactc    120

ccaggaacgg cccccaaact cctcatctat agtaataatc agcgaccctc aggggtccct    180

gaccgattct ctggctccaa gtctggcact tcagcctccc tggccatcag tgggctccag    240

tctgaggatg aggctgatta ttactgttct gcttgggatg attatcttca tggaactgtg    300

ttcggcggag ggaccaagct gaccgtcctg                                     330


<210>  62
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody codon-optimised clone C4

<400>  62
cagagcgtcc tgacacagcc cccttccgca agtggaaccc ctgggcagcg agtgactatt     60

tcatgcagtg gatcttcatc taacatcaag ttcaactccg tgaattggta tcagcagctg    120

cccggaactg ctcctaaact gctgatctat tctaacaatc agcgaccaag tggcgtcccc    180

gaccggttca gcggctccaa gtctgggacc agtgcctcac tggctattag cgggctccag    240

tccgaggacg aagcagatta ctattgcagc gcctgggacg attacctgca cggcaccgtg    300

ttcggaggag gaacaaaact gaccgtcctg                                     330


<210>  63
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody clone D4

<400>  63
cagtctgtgc tgactcagcc cccctcagcg tccgggaccc ccgggcagag ggtcaccatc     60

tcttgttctg gaagcagctc caacatcaaa tttaacagtg ttaactggta tcagcaactc    120

ccaggaacgg cccccaaact cctcatctat agtaataatc agcgaccctc aggggtccct    180

gaccgattct ctggctccaa gtctggcact tcagcctccc tggccatcag tgggctccag    240

tctgaggatg aggctgatta ttactgtgct tcttgggatg attatgttcg tggaactatg    300

ttcggcggag ggaccaagct gaccgtcctg                                     330


<210>  64
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody clone E1

<400>  64
cagtctgtgc tgactcagcc cccctcagcg tccgggaccc ccgggcagag ggtcaccatc     60

tcttgttctg gaagcagctc caacatcaaa tttaacagtg ttaactggta tcagcaactc    120

ccaggaacgg cccccaaact cctcatctat agtaataatc agcgaccctc aggggtccct    180

gaccgattct ctggctccaa gtctggcact tcagcctccc tggccatcag tgggctccag    240

tctgaggatg aggctgatta ttactgttct tcttgggatg attttcttcg tggaactgtt    300

ttcggcggag ggaccaagct gaccgtcctg                                     330


<210>  65
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody clone F2

<400>  65
cagtctgtgc tgactcagcc cccctcagcg tccgggaccc ccgggcagag ggtcaccatc     60

tcttgttctg gaagcagctc caacatcaaa tttaacagtg ttaactggta tcagcaactc    120

ccaggaacgg cccccaaact cctcatctat agtaataatc agcgaccctc aggggtccct    180

gaccgattct ctggctccaa gtctggcact tcagcctccc tggccatcag tgggctccag    240

tctgaggatg aggctgatta ttactgttct tcttgggatg atgatgctcg tggaactatt    300

ttcggcggag ggaccaagct gaccgtcctg                                     330


<210>  66
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody clone G1

<400>  66
cagtctgtgc tgactcagcc cccctcagcg tccgggaccc ccgggcagag ggtcaccatc     60

tcttgttctg gaagcagctc caacatcaaa tttaacagtg ttaactggta tcagcaactc    120

ccaggaacgg cccccaaact cctcatctat agtaataatc agcgaccctc aggggtccct    180

gaccgattct ctggctccaa gtctggcact tcagcctccc tggccatcag tgggctccag    240

tctgaggatg aggctgatta ttactgtgct gcttgggatg atgtttatta tggaactatt    300

ttcggcggag ggaccaagct gaccgtcctg                                     330


<210>  67
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody clone G2

<400>  67
cagtctgtgc tgactcagcc cccctcagcg tccgggaccc ccgggcagag ggtcaccatc     60

tcttgttctg gaagcagctc caacatcaaa tttaacagtg ttaactggta tcagcaactc    120

ccaggaacgg cccccaaact cctcatctat agtaataatc agcgaccctc aggggtccct    180

gaccgattct ctggctccaa gtctggcact tcagcctccc tggccatcag tgggctccag    240

tctgaggatg aggctgatta ttactgtgct tcttgggatg attctcttta tggaactgtt    300

ttcggcggag ggaccaagct gaccgtcctg                                     330


<210>  68
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody clone G10

<400>  68
cagtctgtgc tgactcagcc cccctcagcg tccgggaccc ccgggcagag ggtcaccatc     60

tcttgttctg gaagcagctc caacatcaaa tttaacagtg ttaactggta tcagcaactc    120

ccaggaacgg cccccaaact cctcatctat agtaataatc agcgaccctc aggggtccct    180

gaccgattct ctggctccaa gtctggcact tcagcctccc tggccatcag tgggctccag    240

tctgaggatg aggctgatta ttactgtgct gcttgggatg atgcttatta tggaactatt    300

ttcggcggag ggaccaagct gaccgtcctg                                     330


<210>  69
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody clone H4

<400>  69
cagtctgtgc tgactcagcc cccctcagcg tccgggaccc ccgggcagag ggtcaccatc     60

tcttgttctg gaagcagctc caacatcaaa tttaacagtg ttaactggta tcagcaactc    120

ccaggaacgg cccccaaact cctcatctat agtaataatc agcgaccctc aggggtccct    180

gaccgattct ctggctccaa gtctggcact tcagcctccc tggccatcag tgggctccag    240

tctgaggatg aggctgatta ttactgtgct tcttgggatg atgtttatcg tggaactgtt    300

ttcggcggag ggaccaagct gaccgtcctg                                     330


<210>  70
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody codon-optimised clone H4

<400>  70
cagagcgtcc tgacacagcc cccaagcgca agcggaaccc ccggccagcg agtgaccatt     60

agttgtagtg gaagtagtag taacatcaag ttcaactccg tgaattggta tcagcagctg    120

cccggaactg ctcctaaact gctgatctat tctaacaatc agcgaccaag tggcgtcccc    180

gaccggttca gcggctccaa gtctgggacc agtgcctcac tggctattag cgggctccag    240

tccgaggacg aagcagatta ctattgcgcc agctgggacg atgtgtacag gggcaccgtc    300

ttcggcgggg gaacaaaact gaccgtcctg                                     330


<210>  71
<211>  330
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of light chain variable 
       domain sequence for anti-PD-1 antibody clone H9

<400>  71
cagtctgtgc tgactcagcc cccctcagcg tccgggaccc ccgggcagag ggtcaccatc     60

tcttgttctg gaagcagctc caacatcaaa tttaacagtg ttaactggta tcagcaactc    120

ccaggaacgg cccccaaact cctcatctat agtaataatc agcgaccctc aggggtccct    180

gaccgattct ctggctccaa gtctggcact tcagcctccc tggccatcag tgggctccag    240

tctgaggatg aggctgatta ttactgttct tcttgggatg attctcttta tggaactatt    300

ttcggcggag ggaccaagct gaccgtcctg                                     330


<210>  72
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody clone A3

<400>  72
caggtccagc tggtgcagtc cgggggaggc gtggtccagc ctgggcggtc cctgagactc     60

tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactac    180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat    240

ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagtgatctt    300

ggtgctggtc cttattatta tggtaaggat cattggggcc aagggaccac ggtcaccgtc    360

tcaagc                                                               366


<210>  73
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody clone A10

<400>  73
caggtccagc tggtgcagtc tgggggaggc gtggtccagc ctgggcggtc cctgagactc     60

tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactac    180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat    240

ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagtgatctt    300

ggtgctggtc cttattatta tggtaaggat gtttggggcc aagggaccac ggtcaccgtc    360

tcaagc                                                               366


<210>  74
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Encoded amino acid sequence of heavy chain 
       variable domain sequence for anti-PD-1 antibody codon-optimised 
       clone A10

<400>  74

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Asp Leu Gly Ala Gly Pro Tyr Tyr Tyr Gly Lys Asp Val Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  75
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody codon-optimised clone A10

<400>  75
caggtgcagc tggtcgaatc cggggggggg gtggtgcagc ctggacggtc actgagactg     60

agttgtgccg cctctgggtt tactttcagc tcctatggca tgcactgggt gaggcaggct    120

cccggcaagg ggctggagtg ggtggcagtc atctcttacg acggcagtaa caagtactat    180

gccgatagcg tcaaagggcg gttcactatt tcaagagaca acagcaaaaa taccctgtac    240

ctccagatga acagcctgcg ggccgaagac acagctgtgt actattgcgc atctgatctg    300

ggagccggcc cttactatta cggcaaggat gtctgggggc agggaaccac agtcaccgtc    360

tcaagc                                                               366


<210>  76
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody clone B6

<400>  76
caggtccagc tggtagagtc cgggggaggc gtggtccagc ctgggcggtc cctgagactc     60

tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactac    180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat    240

ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagtgattat    300

ggtgctggtc cttattatta tggtatggat gtttggggcc aagggaccac ggtcaccgtc    360

tcaagc                                                               366


<210>  77
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody codon-optimised clone B6

<400>  77
caggtgcagc tggtggaaag cggggggggc gtggtgcagc ctggaaggtc actgagactg     60

tcttgtgccg catctgggtt tacatttagc tcctatggca tgcactgggt gaggcaggct    120

cccggcaagg ggctggagtg ggtggcagtc atctcttacg acggcagtaa caagtactat    180

gccgatagcg tcaaagggcg gttcactatt tcaagagaca acagcaaaaa taccctgtac    240

ctccagatga acagcctgcg ggccgaagac acagctgtgt actattgcgc atctgattac    300

ggagccggcc cttactatta cggcatggat gtctgggggc agggaaccac agtcaccgtc    360

tcaagc                                                               366


<210>  78
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody clone C4

<400>  78
caggtccagc tggtagagtc cgggggaggc gtggtccagc ctgggcggtc cctgagactc     60

tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactac    180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat    240

ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagtgatctt    300

ggtgctggtc cttattatta tggtttggat gtttggggcc aagggaccac ggtcaccgtc    360

tcaagc                                                               366


<210>  79
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody codon-optimised clone C4

<400>  79
caggtgcagc tggtggaatc tggggggggg gtcgtgcagc ccggacggtc actgagactg     60

tcatgtgccg cttcagggtt tacttttagc tcctatggca tgcactgggt gaggcaggct    120

cccggcaagg ggctggagtg ggtggcagtc atctcttacg acggcagtaa caagtactat    180

gccgatagcg tcaaagggcg gttcactatt tcaagagaca acagcaaaaa taccctgtac    240

ctccagatga acagcctgcg ggccgaagac acagctgtgt actattgcgc atctgatctg    300

ggagccggcc cttactatta cggcctggat gtctgggggc agggaaccac agtcaccgtc    360

tcaagc                                                               366


<210>  80
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody clone D4

<400>  80
caggtccagc tggtagagtc cgggggaggc gtggtccagc ctgggcggtc cctgagactc     60

tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactac    180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat    240

ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagtgatctt    300

ggtgctggtc cttattatta tggtatggat gtttggggcc aagggaccac ggtcaccgtc    360

tcaagc                                                               366


<210>  81
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody clone E1

<400>  81
caggtccagc tggtagagtc cgggggaggc gtggtccagc ctgggcggtc cctgagactc     60

tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactac    180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat    240

ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagtgatctt    300

ggtgctggtc cttattatta tggtatggat gtttggggcc aagggaccac ggtcaccgtc    360

tcaagc                                                               366


<210>  82
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody clone F2

<400>  82
caggtccagc tggtagagtc cgggggaggc gtggtccagc ctgggcggtc cctgagactc     60

tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactac    180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat    240

ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagtgatctt    300

ggtgctggtc cttattatta tggtatggat gtttggggcc aagggaccac ggtcaccgtc    360

tcaagc                                                               366


<210>  83
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody clone G1

<400>  83
caggtccagc tggtagagtc cgggggaggc gtggtccagc ctgggcggtc cctgagactc     60

tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactac    180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat    240

ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagtgatctt    300

ggtgctggtc cttattatta tggtatggat gtttggggcc aagggaccac ggtcaccgtc    360

tcaagc                                                               366


<210>  84
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody clone G2

<400>  84
caggtccagc tggtagagtc cgggggaggc gtggtccagc ctgggcggtc cctgagactc     60

tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactac    180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat    240

ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagtgatctt    300

ggtgctggtc cttattatta tggtatggat gtttggggcc aagggaccac ggtcaccgtc    360

tcaagc                                                               366


<210>  85
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody clone G10

<400>  85
caggtccagc tggtagagtc cgggggaggc gtggtccagc ctgggcggtc cctgagactc     60

tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactac    180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat    240

ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagtgattat    300

ggtgctggtc cttattatta tggtatggat gtttggggcc aagggaccac ggtcaccgtc    360

tcaagc                                                               366


<210>  86
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody clone H4

<400>  86
caggtccagc tggtagagtc cgggggaggc gtggtccagc ctgggcggtc cctgagactc     60

tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactac    180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat    240

ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagtgatctt    300

ggttctggtt attatcttta tggtatggac gtctggggcc aagggaccac ggtcaccgtc    360

tcaagc                                                               366


<210>  87
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody codon-optimised clone H4

<400>  87
caggtgcagc tggtggagag cggggggggg gtggtgcagc ctggacggtc actgagactg     60

agttgcgccg catctggatt cacatttagc tcctacggca tgcactgggt gaggcaggca    120

cccggcaagg ggctggagtg ggtggccgtc atctcttatg acggcagtaa caagtactat    180

gctgatagcg tcaaagggcg gttcactatt tcaagagaca acagcaaaaa taccctgtac    240

ctccagatga atagcctgcg ggccgaagac acagctgtgt actattgcgc ctccgatctg    300

ggatctggct actatctgta tggcatggat gtctgggggc agggaaccac agtcaccgtc    360

tcaagc                                                               366


<210>  88
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Nucleotide sequence of heavy chain variable 
       domain sequence for anti-PD-1 antibody clone H9

<400>  88
caggtccagc tggtagagtc cgggggaggc gtggtccagc ctgggcggtc cctgagactc     60

tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactac    180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat    240

ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagtgatctt    300

ggtgctggtc cttattatta tggtatggat gtttggggcc aagggaccac ggtcaccgtc    360

tcaagc                                                               366


<210>  89
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: HC-CDR1

<400>  89

Ser Tyr Gly Met His 
1               5   


